新天药业(002873) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥524,537,902.78, representing a 15.53% increase compared to ¥454,031,233.06 in the same period last year[23]. - The net profit attributable to shareholders was ¥57,447,639.37, up 22.65% from ¥46,837,320.12 in the previous year[23]. - Basic earnings per share increased by 18.48% to ¥0.3469, compared to ¥0.2928 in the previous year[23]. - The company reported a net profit excluding non-recurring gains and losses of ¥55,472,739.77, a 19.06% increase from ¥46,590,801.43 in the same period last year[23]. - The company achieved a revenue of ¥524,537,902.78, representing a year-on-year increase of 15.53% compared to ¥454,031,233.06 in the previous year[53]. - The company's main business revenue reached ¥524.1 million, representing a year-on-year increase of 15.55%[55]. - The net profit for the first half of 2022 was CNY 67,436,924.64, representing a 22.1% increase from CNY 55,092,402.91 in the previous year[168]. - The total comprehensive income for the first half of 2022 was CNY 68,806,549.84, compared to CNY 59,299,116.77 in the first half of 2021, indicating a growth of 16.4%[173]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,621,253,562.39, a 6.35% increase from ¥1,524,426,501.68 at the end of the previous year[23]. - The company's total assets reached CNY 1,614,133,879.25, compared to CNY 1,529,630,827.36 at the beginning of the year, reflecting a growth of 5.5%[164]. - The total liabilities increased to CNY 653,020,092.21, up from CNY 644,189,946.00, indicating a rise of 1.3%[165]. - The company's asset-liability ratio stands at 41.11%, a slight decrease of 0.48% from the previous year[156]. Cash Flow - The net cash flow from operating activities decreased by 26.40% to ¥43,965,639.45, down from ¥59,736,164.46 in the same period last year[23]. - The company's cash and cash equivalents increased by 489.41%, reaching ¥55,165,108.36, mainly due to reduced bank loan repayments and increased bank borrowings[53]. - The ending balance of cash and cash equivalents was ¥85,559,440.63, compared to ¥234,174,509.64 at the end of the first half of 2021, reflecting a decrease of 63.4%[178]. - The total cash outflow for operating activities was ¥504,632,815.44, which increased by 29.0% from ¥391,065,369.54 in the previous year[177]. Research and Development - The company has completed clinical phase III trials for three new traditional Chinese medicine products, including Longcen Pelvic Comfort Granules[36]. - The company has a strategic focus on expanding its market presence and enhancing its product portfolio through continuous research and development[36]. - The company's R&D investment increased to ¥13,972,036.81, up 17.51% from ¥11,889,702.71 in the previous year, reflecting a growing commitment to innovation[53]. - Research and development expenses for the first half of 2022 were CNY 12,384,704.15, a decrease of 14.7% compared to CNY 14,520,861.28 in the same period of 2021[172]. Market and Product Development - The company has a focus on gynecological and urological medications, with products like Ningpitai Capsule and Kucan Gel being unique in the domestic market[33][34]. - The leading product, Kuntai Capsule, is a national essential drug and has ranked 2nd in the gynecology medication field in the 2020 and 2021 Clinical Value Chinese Medicine Brand List[32]. - The company has established a stable supply chain for raw materials, leveraging the rich medicinal resources available in Guizhou province, which accounts for 89.81% of the 363 key varieties surveyed nationwide[51]. - The company is focused on expanding its market reach, with its products covering over 11,500 hospitals and 85,000 retail outlets nationwide[50]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, ensuring compliance with environmental regulations[95]. - The company emphasizes social responsibility by protecting investor rights, enhancing employee welfare, and engaging in community service[104]. - The company has introduced advanced energy-saving and environmental protection equipment to improve fuel utilization and reduce carbon emissions[103]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. Shareholder and Equity Information - The total number of shares before the change was 164,048,027, with a total after the change of 165,721,702, reflecting an increase of 1,673,675 shares[132]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 36.55% of the shares, totaling 60,576,547 shares, with 33,821,441 shares pledged[135]. - The company has not disclosed any significant impacts on financial metrics such as basic and diluted earnings per share due to the share changes[134]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[139].